Company: WHWK
Filing Date: 2025-05-13
Form Type: CORRESP
Source: 0001193125-25-119011
Chunk: 0

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-05-13
Form: CORRESP
Chunk 0
---
| Wilson Sonsini Goodrich & Rosati                      
 Professional Corporation                              
 12235 El Camino Real San Diego, California 92130-3002 
 O: 858.350.2300                                       
 F: 858.350.2399                                       |

May 13, 2025 VIA EDGAR AND OVERNIGHT DELIVERY U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549

| Attention: |     | Daniel Crawford Joe                                   
 McCann                                                |
| Re:        |     | Whitehawk Therapeutics, Inc.                          
 Form 10-K for the fiscal year ended December 31, 2024 
 Filed February 27, 2025 File No. 001-38560            |

Ladies and Gentlemen: On behalf of our client, Whitehawk Therapeutics, Inc. (the “ Company”), we submit this letter in response to comments from the staff (the “ Staff”) of the U.S. Securities and Exchange Commission (the “ Commission”) contained in its letter dated May 7, 2025 (the “ Comment Letter”), regarding the above-referenced Annual Report on Form 10-K(File No. 001-38560 )of the Company, filed on February 27, 2025 (the “ Annual Report”). In this letter, we have recited the comments from the Staff in italicized, bold type and have followed each comment with the Company’s response. References to “we,” “our” or “us” mean the Company or its advisors, as the context may require. Annual Report on Form 10-KFiled February 27, 2025 Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations. Recent Developments, page 103

| 1. | Please confirm that in future filings, wherever you disclose the material terms of your License        
 Agreement with WuXi Biologics, you will also disclose the royalty term and the termination provisions. |

AUSTIN BOSTON BOULDER BRUSSELS HONG KONG LONDON LOS ANGELES NEW YORK PALO ALTO SALT LAKE CITY SAN DIEGO SAN FRANCISCO SEATTLE SHANGHAI WASHINGTON, DC WILMINGTON, DE

Securities and Exchange Commission

May 13, 2025

Page
2

In response to the Staff’s comment, the Company updated its MD&A disclosure on p.